Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Emily H. Castellanos
Based on 2 articles published since 2009
(Why 2 articles?)
||||

Between 2009 and 2019, Emily Castellanos wrote the following 2 articles about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Review Current treatment options for pancreatic carcinoma. 2011

Castellanos, Emily / Berlin, Jordan / Cardin, Dana Backlund. ·Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. ·Curr Oncol Rep · Pubmed #21491194.

ABSTRACT: Pancreas cancer is a significant cause of cancer mortality; therefore, the development of early diagnostic strategies and effective treatment is essential. Improvements in imaging technology, as well as use of biomarkers such as CA 19-9, are changing the way that pancreas cancer is diagnosed and staged. Although progress in treatment for pancreas cancer has been incremental, development of combination therapies involving both chemotherapeutic and biologic agents is ongoing. This article reviews current strategies in the diagnosis and treatment of resectable and advanced pancreas cancer.

2 Review Treatment of early-stage pancreatic cancer. 2011

Castellanos, Emily H / Cardin, Dana B / Berlin, Jordan D. ·Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232-6307, USA. ·Oncology (Williston Park) · Pubmed #21456390.

ABSTRACT: Pancreatic cancer is the fourth leading cause of cancer death, and it is estimated that over 43,000 people would be diagnosed with and over 36,000 people would die of pancreatic cancer in the United States in 2010. Surgical resection remains the only chance for possible cure, but only 15% to 20% of patients newly diagnosed with pancreatic cancer are considered for surgical resection. Of these, the median five-year survival rate is still less than 20%, with most resections resulting in recurrent disease. This suggests that even seemingly resectable pancreatic cancer has microscopic systemic spread before operative intervention occurs. Both adjuvant and neoadjuvant therapies have been studied in an effort to improve survival for patients with resectable pancreatic cancer.